The most common ICBs refer to blocking immune inhibitory receptors CTLA4 and PD‐1 on T cells, or PD‐L1 on tumor cells and tumor‐infiltrating immune cells using antagonistic antibodies. This evidence concerns the gene CTLA4 and neoplasm.